Research in Today’s Dynamic Chinese Market

2

Agenda

1 Chinese Market Overview

2 China’s Pharmaceutical Market

3 Advertising & Market Research

4 China’s Pharma Market Research

3

China – A country goes back 6,000 Years ….

4

…& the Last 10 Years with drastic changes

5

China Basic Facts…

Area : 9.6 million sq.km

Capital : Beijing

Population : 1321.29 million

Family HH : 406 million

Average HH size : 3.01

Ave. Income : 15,781RMB (urban)

Per Capita 4,761RMB(rural)

Source: China Statistical Year Book 2008

China Now A Huge Consumer Market

Raw Materials & Consumer Goods

Source : Fortune Magazine

% of World’s Consumption

Chinese Consumer Ownership Aspirations

1970’s Bicycle, Sewing Machine, Radio

1980’s TV, Washer, Refrigerator

1990’s DVD Player , Motor Cycle, Mobile Phone

2000 … Apartments, Cars, Home PC’s, Luxury Goods

Explosive Economic Development

Booming Urban Middle Class Consumer Base

Real

Estate

Boom

“Bubble”

3rd Largest

Car

Market

2nd Largest

PC

Market

11% of

World’s

Luxury

Goods

Economic Growth & Consumerism Concentration

Eastern Seaboard & Main Urban Centers

Myth Of 1.3 Billion Consumers

30% “Middle Class” Consumers In Urban Centers : 350-400 M

5% “High End” Consumers : 60 M

Henan

Jilin

Shanxi

ShaanxiAnhui

Jiangxi

Qinghai

Guizhou

Liaoning

Hubei

Hunan

Guangxi

Sichuan

Yunnan

Tibet

Hainan

Xinjiang Uygur

Hebei

Heilongjiang

Inner Mongolia

GansuShandong

Jiangsu

Zhejiang

Fujian

Guangdong

Beijing

Tianjin

Shanghai

30% Of Population

In Urban Areas

350-400 Million

70% Of Population

In Rural Areas

900 Million

65%

Ad Spend

China economic growth records a

slow-down in 2008.

Area : 9.6 million sq.km

Capital : Beijing

Population : 1321.29 million

Family HH : 406 million

Average HH size : 3.01

Ave. Income : 15,781RMB (urban)

Per Capita 4,761RMB(rural)

Source: China Statistical Year Book 2008

The GDP growth rate declined from 11.4% in 2007 to 9% in 2008.

In the whole year of 2008, the export increases by 19% on a year-on-year basis,

which, actually drops by 8.6 percent in comparison with the same period last

year.

Foreign currency reserve USD 2000 billion+ till the end of 2008.

Per capita expenditure in urban area from RMB 4, 998 in 2000 to RMB 8,446 in 1-

3 quarters.

Per capita dispensable income in urban area from RMB 6,280 in 2000 to RMB

12400 in 2008,rising 14% .

10

CHINA Future GDP Growth

Source: 2008E from CIA factbook; 2025 from World Bank, NBS, Goldman Sachs, EIU

14.3

4.24.8

3.8

1.2 1.7

18.3

10.2

6.1

3.6 3.2

1.7

0

2

4

6

8

10

12

14

16

18

20

USA China Japan Germany India Brazil

CAGR 08–25

GDP / Capita

by 2025 (KUSD)

Total GDP

in $US Trillion

0%5.6%(0.3)%1.3%5.1%1.4%

52.5 7.1 50.8 44.7 2.3 7.8

2008E 2025

How Confident Are Chinese Consumers

2006 H1

No change

2007 H1

+1%

2007 H2

-8%

2008 H1

-3%

2008 H2

+1%

Stable Consumer Confidence Index in China

While other countries’ consumers may be struggling to keep their heads above water,

more than 72% of Chinese consumers -living in one of the fastest growing economies in

the world-are optimistic that their country is not currently in a recession - nearly twice

that of the global average(37%).

Source : 2008 Nielsen Media Special Report

China Consumer Confidence Index

12

On the Road to Be a Giant…

Private Consumption (US$ billion)

330

340

350

420

650

700

900

1,500

2,900

5,000

1995 2005 2015E

500

600

650

1,000

1,000

1,200

1,400

1,700

2,600

8,700

Rank

1

2

3

4

5

6

7

8

9

10

CAGR

95–05

Percent

6

-1

1

3

7

5

5

6

11

6

CAGR

05–15

Percent

5

7

4

6

5

5

14

6

6

3

US

Japan

Germany

France

UK

Italy

Brazil

Spain

China

Canada

US

Japan

Germany

UK

France

Italy

China

Spain

Canada

Mexico

US

Japan

China

Germany

UK

France

Italy

India

Spain

Russia1,100

1,200

1,300

1,700

2,000

2,400

2,500

3,700

5,000

14,000

Source: Global insights; EIU

13

Male Female

Population, Thousands

Source: McKinsey

Growth of Aging Population

14

Aging and Evolving Life Style Are Shifting Disease Profiles

Towards That of Western Diseases

From 2004 to 2024:

• The number of people over 60 years of age increase by 106%

• The number of people under 15 years of age reduce by 40%

231,762

225,878

342,587

324,936

159,136

174,531

168,395

317,913

418,322

230,556

139,241

118,054

290,028

427,331

328,385

0 100,000 200,000 300,000 400,000 500,000

0–14

15–24

25–39

40–59

60+

2004 2014 2024

Ag

e G

rou

p

Persons ‘000s

The ageing of the population alone is predicted to produce a 200% increase in deaths from cardiovascular disease in China between the years 2000 and 2040

Typically, those over 40 spend 3–4 times more on healthcare than those under 40 years, which means the healthcare demand will dramatically increase

Source: Asian Demographics, Healthcare 2006

15

Increasing Prevalence of Chronic Disease Raise Tremendous

Healthcare Needs

Causes of Chronic Diseases

13.1

7.1

4.1

2.3

8.1

3.21.9

0.7

0

5

10

15

20

Large City Middle-sized

City

Wealthy Rual

Villages

Poor Rural

Villages

Pro

po

rtio

n (

%)

Overweight Obese

Percentages of children aged 7–17 years who were overweight and obese in China, 2002

Underlying Socioeconomic, Cultural Political and Environmental Determinants

Globalization

Urbanization

Population Aging

Common Modifiable Risk Factors

Unhealthy diet

Physical inactivity

Tobacco use

Non-modifiable risk factors

Age

Heredity

Intermediate Risk Factors

Raised blood pressure

Raised blood glucose

Abnormal blood lipids

Overweight / obesity

Main Chronic Diseases

Heart disease

Stroke

Cancer

Chronic respiratory diseases

Diabetes

16

13,03015,703

17,637

22,167

28,090

34,916

42,982

52,438

63,187

75,319

28.6

20.5

12.3

25.626.7

24.323.1

2220.5

19.2

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

2004 2005 2006 2007 2008 2009E 2010E 2011E 2012E 2013E

0

5

10

15

20

25

30

35

40

45

50

The Pharma market kept fast growth in 2008 and will keep

around 21.2% growth rate in the next five years

Trend of China Hospital Market at Ex-

Manufacturer price

Source: IMS CHPA, IMS Prognosis Mar. 09, update，Note: Exchange rate=6.834, market defined as hospital sector at hospital

purchase price

(2007Q3MAT Growth rate=22%)

Anti-corruption campaign

04~08 CAGR 21.2%

09~13 CAGR 21.2%

17

Under-investment and inequitable distribution of resources in China's fragmented, hospital-led

healthcare system have contributed to wide disparities in healthcare provision between eastern and

western, urban and rural and among income groups.

Under-developed health insurance

system with limited coverage

Covered ~40% Urban, ~ 80% rural

(under-funded and only basic care)

Government offers insurance

coverage mostly for urban

employed

A major priority for the government

is to broaden insurance coverage

80% of hospitals (19,852 in 2007)

are state-owned with low

efficiency, heavy reliance on drug

profit

~80% drugs are sold in the

hospital channel, retail market

growth faster than hospital one

and is driven by increasing of

Pharmacies (~320,000 in 2007)

and heavy investment from MNC

and local companies

Distribution industry fragmented

(>7000 wholesalers in the market,

Top 3 takes only 19% MS)

The supply chain is also

fragmented as distributors

continue to operate along regional

lines.

Involving three tiers of

distributors, manufacturers work

with hundreds of distributors to

cover significant geographical

spread

Multiple government agencies (>12 ministries or agencies) involved in policy setting and

with little co-ordination, different interests leading to slow decision making as seeing in

the healthcare reform efforts

Payer Provider Supplier

Government

Urbanization, rising wealth and increasing health awareness drive growth of fundamental healthcare demand

Health care spending differs greatly by region and city tiers

Aging and evolving life style are shifting the disease profiles toward that of developed countries

Patients

18

China health care spending has grown faster than GDP

Likely to reach 6-7% of GDP by 2015

3

6

9

12

15

0 10 20 30 40 50

Source: China Statistical Yearbooks

1. Economy

Part of Economic incentive program to drive

domestic consumption requirement

Sustained rapid GDP growth led to increasingly

higher affluence, living standards, education levels,

HC-awareness

Increasing availability of higher quality, high priced

drugs

HC % of GDP

GDP/CAP ($K)

China

2004

Poland

Hungary

Mexico

Korea

Greece

Spain

Taiwan

Germany

CanadaFranc

eItaly

JapanUK

SingaporeHK

US

Switzerland

High growth path

Low growth

path

China 2015

Key

drivers

Healthcare spending grown faster than GDP

Healthcare estimated to reach 6-7% GDP by

2015

2. Demographics

Population growing and aging

Changes in lifestyle with affluence

3. HC financing

Improving social security system

Medical service are priced low in

China

Hospitals need to finance

themselves

13%

10%

14%15%14%

15%14%

15%

10%11%11%

10%

9%8%

10%

8% 8%

10%

0%

4%

8%

12%

16%

1999

2000

2001

2002

2003

2004

2005

2006

2007

HC spend

as % of

GDP

4.9% 5.1% 5.2% 5.4% 5.6% 5.6%

GDP growth

HC spend growth

4.7% 4.7% 4.5%

Heath

care

expense

control

19

21%12%

6%7%

3%

42%40%

34%

7%

7%

9%

20%25%

42%

51%

25%

16%

28%

2%

4%

# of Hospitals # of Drs Yearly patient vistis Drug Usage

Level III Grade A

Level III Grade B&C

Level II

Level I

No level

Total: 1,049,946 1,637m 27.8 USD bn18,899

Source: MOPH 2007 hospital and doctor database; Exchange rate:6.834

* Including assistant doctor

Potential distribution by hospital levels (2007)

Currently the major market potential is concentrated in big

hospitals

Hospital Levels

High

Low

20

Accelerate improving health care accessibility, efficiency and

quality are the key objectives of China Health Care reform

Accelerate expansion

of Basic

reimbursement

coverage

Reimbursement coverage (Urban Residence,

employee BMI and Rural co-operative ) >90% before

2012

Per capita government subside increase to 120 RMB

per year, and rise individual premium contribution

Rise reimbursement percentage and maximum payout

limits

Top 5 Focus areas Key initiatives Impact to Market

Significant improving of health

care accessibility need more

geographic coverage

Pricing would be a big

challenge to overcome

Establish National

essential drug

system

Drug in the list will be supplied by government

All essential drugs will be included in the national

drug reimbursement list for basic medical insurance

programs

The listed product will be

widen penetration, but also

face price cut.

Optimize primary

health care service

system

Infrastructure building will be strengthened for county

central hospitals (including TCM ), township health

centers, village clinics in remote areas

Urban community healthcare service centers

Community hospital and

county central hospital play

more and more important

roles in drug deliver system

Improve access to

basic public health

services

Increase investment in public health

Setup national wise residents health records

Promote TCM in prevention and clinical usage

Leverage TCM opportunity

Disease management

program cooperate with

government

Promote public

hospital reform

Separation of dispensing from prescribing

Pharmacy split from hospital

Encouraging private hospitals

Hospital tendering

More complex challenge lie

in hospital listing, prescription

management etc.

And by 2011, the Chinese pharmaceutical market will be the 6th largest in

the world.

1. USA

2. Japan

3. France

4. Germany

5. Italy

6. UK

7. Spain

8. Canada

9. China

10. Brazil

11. Mexico

12. S.Korea

Top 12 pharmaceutical markets, 2006 Top 12 pharmaceutical markets, 2011

Source: IMS Market Prognosis 2008

Estimated China Pharma Market Size for Ethical and OTC Drug at ex-factory level excluding TCM (US$ Billions)

1. USA

2. Japan

3. Germany

4. France

5. UK

6. China

7. Italy

8. Canada

9. Spain

10. Brazil

11. Mexico

12. S.Korea

22

Agenda

1 Chinese Market Overview

2 China’s Pharmaceutical Market

3 Advertising & Market Research

4 China’s Pharma Market Research

Internet Explosion,

Information, Chatting, & Downloading

4.

Channel

Proliferation

Internet Users

F20-45 PMI 3000+

Information 57%

Reading Articles 52%

Email 42%

Chat 32%

Playing Games 22%

Download Software 19%

Download Movies / MP3 13%

Shopping 10%

Source : Internet World Stats, CNNIC, CMMS

32 m

35 m

39 m

46 m

67 m

94 m

201 m

0 100 200

USA

China

Japan

Germany

India

UK

Korea

Internet Users Millions

68% Penetration

7%

53%

56%

4%

59%

63%

China 123 Million Netizens

123m

Digital Media Type

In-house LCD Media

Office Net

Hotel Net

Hospital Net

Club and Restaurant

(entertaining and leisure lifestyle)

Apartment Building

Supermarket Net

Public Transportation LCD Media

Bus LCD

Metro LCD

Taxi LCD

In-flight LCD /Airport LCD

Out of Home

27

0

100

200

300

400

500

600

Y02 Y03 Y04 Y05 Y06 Y07 Y08

MG

NP

TV

Advertising Expenditure – Robust Growth

RMB 198.8billion

RMB 261.4billion

RMB 139.5 billion

+43%

+32% RMB 315.7billion

+21%

RMB Billion

RMB 386.7billion

+22% RMB 520.4billion

+35%

Source : Nielsen Media Research – AdQuest Millennium

28

Advertising Expenditure – Top 10 Industries 2008

RMB billion

+53%

+5%

+22%

+31%

+23%

+34%

+54%

+14%

+3%

% increase

vs. 07

+26%

0 20 40 60 80 100

TELECOMMUNICATION

PROPERTY

MISCELLANEOUS

AUTOMOTIVES

RETAIL & SERVICE

FOODSTUFFS

BUSINESS/INDUSTRIAL/AGRICULTURE

BEVERAGES

TOILETRIES

PHARMACEUTICALS & HEALTH

PRODUCT

Source : Nielsen Media Research – AdQuest Millennium

29

AP market research market growth exceed western countries

Source: ESOMAR Global Market Research report 2008

30

China, Indian and Rejuvenated tiger economies of southeast of

Asia drive the growth of the region

Skilled professionals are moving within the

region with Indians relocating to other

parts of Asia and Mandarin speakers from

Malaysia and Singapore moving to China

Source: ESOMAR Global Market Research report 2008

31

China ranks 9th globally in 2007; TNS predicts China's Market Research

industry to overtake Japan around 2012 to become the fifth largest globally

Global Top 10 Market Research Market 2007

8726

2771 2659 2644

1518

858 768 730 712 623

6%

17%

21%19%

5%

22%

17%

26%

22%

17%

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

10000

USA UK Germany France Japan Italy Canada Spain China Australia

Mio

US

D

0%

5%

10%

15%

20%

25%

30%

07 Market Size Growth

Source: ESOMAR Global Market Research report 2008

32

China ranks 8th globally, in terms of market spend in market research. Money spent

with market research agencies in China has doubled in the last 5 years.

China MR market Turnover 03-07

306

371

475

583

712

21%

28%

23%22%

0

100

200

300

400

500

600

700

800

2003 2004 2005 2006 2007

Mio

US

D

0%

5%

10%

15%

20%

25%

30%

China MR turnover

Growth

Source: ESOMAR Global Market Research report 2008

0%

20%

40%

60%

80%

FMCG Durable Auto Telcom Finace Healthcare IT Advertising Industry Retail

Top 10 Industry of MR

Source: China MR Association

China Overall Market - MR Agency Revenue

34

China is the fast-emerging market

35

MR turnover in 2007 (US $m)

Ad spend in

2007 (US $m)

Population

Per 2007

MR spend per capita

(US$m)

Ad spend per capita (US$m)

MR as % of ad

spend

Australia 623 10,664 20,983,085 29.69 508.24 5.8%

China * 712 48518 1,321,052,495 0.54 36.73 1.5%

France 2,644 14,595 61,676,296 42.87 236.64 18.1%

Germany 2,659 24,306 82,200,004 32.35 295.69 10.9%

Hong Kong *

92 6,311 6,971,685 13.24 905.23 1.5%

India * 151 3,583 1,123,966,698 0.13 3.19 4.2%

Japan 1,518 38,529 127,761,250 11.88 301.57 3.9%

USA 8,726 163,260 301,967,085 28.90 540.65 5.3%

China’s Market Research Market is still underdeveloped

* Source: Advertising spend 2006,Nielsen Media Research

36 36

Top Primary Research Companies

Top Primary Research Companies

Company Name

Industries Served

ACNielsen China

Consumer Packaged Goods, Financial Services, Government & Social, Media, Online, Retailing, Telecommunications, Travel & Tourism

Research International China

pharmaceutical, Biotechnology, Educational institutions, Research & Development Companies, Contract Research Organisations

Sino Market

Research Ltd

IT Industry, Telecommunications, Home Electronics , Fast moving consumer goods, Automobile industry

China

International

Economic

Consultants Co ,

Ltd

power generation and distribution, machine building, auto making, chemical, pharmaceutical, home appliances, food, IT, real estates, banking and retail

ACNielsen China

•Though the AcNielsen Group does cater to the

pharmaceuticals industry globally, but not in China specifically

Research International China

•South China market research firm International (RI China) is

the world's largest specialized market research company

Research International Group (RI) branch in China.

Sino Market Research Ltd

•Sino-MR is a Leading market research & information agency

in China.

•Biggest Telecommunication research agency in China

•Sino-MR is specialized in Retail audits, Consumer research,

Market segmentation, Brand surveys and Product testing in

China.

•China International Economic Consultants Co , Ltd

•Is a wholly-owned subsidiary of its parent company-China

International Trust and Investment Corporation (CITIC)

•At present, CIEC employs more than 300 consultants.

Source : SmartAnalyst

China’s MR market ….

China market research market was approximately US$700 million. Money spent with market research agencies in China has doubled in the last 5 years.

It is predicted that China's Market Research industry to overtake Japan around 2012 to become the fifth largest globally

Over the past three or four years, the volume of market research generated by Chinese companies has been growing much faster than the multinational spend. China’s leading market research agencies are finding that the volume of business they receive from Chinese companies is approaching 50% of turnover.

China primary market research market is estimated around US$ 700, Pharma PMR takes less around 5-6%

Pharmaceutical primary market research is estimated around 35m in terms of spending and 75% spend come from multinational companies.

38

Agenda

1 Chinese Market Overview

2 China’s Pharmaceutical Market

3 Advertising & Market Research

4 China’s Pharma Market Research

39

Big MNC pharma dominate the market and become stronger

Top 20 Corporations in China Hospital Market, 2008

Source: IMS CHPA

Rank

Corporation

Sales value Share Growth EV

2005 2006 2007 2008 US$ m % %

Total China 28,090.1 100.00 26.7 100.0

4 4 2 1 BSP GROUP 533.3 1.90 30.94 103.34

3 2 1 2 ASTRAZENECA GROUP 528.2 1.88 27.86 100.91

2 3 3 3 PFIZER GROUP 521.1 1.86 30.06 102.65

14 8 6 4 SANOFI-AVENTIS GP. 450.0 1.60 29.05 101.85

1 1 4 5 JS.YANGZIJIANG FTY 445.3 1.59 23.37 97.37

5 5 5 6 ROCHE GROUP 385.3 1.37 7.18 84.59

9 6 7 7 JS.L.Y.G. HENGRUI 379.6 1.35 31.31 103.63

11 12 10 8 SHANDONG QILU FTY 372.9 1.33 35.88 107.24

8 9 9 9 HLJ.HAERBIN PHARM. 348.6 1.24 22.80 96.92

6 7 8 10 NOVARTIS GROUP 333.5 1.19 16.86 92.23

34 24 15 11 KE LUN GROUP 317.4 1.13 55.96 123.09

10 10 11 12 GLAXOSMITHKL GROUP 281.2 1.00 18.00 93.13

15 15 13 13 M.S.D. GROUP 280.1 1.00 23.20 97.24

16 13 12 14 SH.ASIA PIONEER PH 261.7 0.93 12.69 88.94

26 18 16 15 NOVO NORDISK GROUP 261.1 0.93 30.69 103.14

28 23 24 16 SHANDONG RUIYANG 243.4 0.87 42.58 112.52

33 25 17 17 GENERTEC GROUP 237.4 0.85 21.82 96.14

49 37 25 18 SHANDONG LUOXIN PH 234.7 0.84 41.56 111.72

7 11 14 19 ZHUHAI LIZHU GROUP 232.3 0.83 11.64 88.11

22 21 22 20 SHUANGHE GROUP 225.4 0.80 21.88 96.19

85 71 63 77 WYETH GROUP 76.1 0.27 10.16 86.94

40

Competitive Environment of Pharma Market Research

Treat of new entrants

Traditional FMCG agency enter

the Pharma &health care MR

market

Client bargaining power

High due to centralized souring

policies and client consolidation

More and more talent jump from

market research agency to

customer side

Supplier Bargaining power

With a highly competitive and a

fragmented supplier base (field

work)

Threat of substitution

Available electronic physician

prescription and patients record

data

Intra-sector competition

High turnover rate >30%, and

talent war exits among the

agencies

M&A with foreign partner to

improve the competiveness

41

Common Pharma research be conducted in China

1 yrs

before launch

2 yrs

before launchLaunch In market

Compound

Customer

Consumer

Competitor

Market Understanding

Profiling

ATU Baseline

Unmet needs and

MKT driver

Concept test Positioning

Message, story flow

Price & Conjoint

Demand & forecasting

Promotional tools

Market Understanding

Disconnects between

patients and physicians

Patients Flow

Unmet needs

Insight Mining

Segmentation

KOL Mapping

ATU pre-launch

Insight Mining

Affordability

Segmentation

Promotional tools

Perception Map

Attributes

Benchmark

Source of business

ATU post-launch

Launch Optimization

Detail aid response test

Brand Mapping

Brand Switch

FF effectiveness

Competitor

promotion

U&A

Customer satisfactory

Message Tracking

Brand Switch

FF effectiveness

Competitive benchmarking

Patients Flow

Direct-to-consumer ad

testing

Market opportunity

Message/Promotion

refinement

New indication

development

Lifecycle management

Brand Personality

DTC tracking

42

Standard Working process in a typical China Pharmaceutical

company

Market research Question

Project design & Execution

Results lead to strategy

Brand Team

Market

Research

What is the real business issues ?

What decision should I make ?

What is my priority?

What is my research assumptions?

When is the best time to do the market research?

Can second hand data answer part of the questions?

Which vendor best understand the research objective?

Are everything I need included in the questionnaire?

Do the research result support my assumption?

What market opportunity should I pursue based on the result?

Do we need to adjust our strategy based on the result?

Which vendor is appropriate for this project?

What kind of method should we take?

For the interviewer: Who, where, how many

Is the sampling representative enough?

Is the result reflect the true market situation？

In what kind of context should we use the result?

Strategic Alignment

43

Market Research Check list to be answered before

launch

Shape the Brand Shape the marketShape the Company

Current & future Market : structure/ size/growth trends (volume & value).

Physician segmentation & targeting

Treatment & Rx Dynamics

KOL mapping

Patient flow & Patients segmentation

Competitive landscape / CI

Marketplace Analysis

SWOT/Key Issues & Opportunities

Source of business

Physician perception

Positioning, key messages, CPP

Forecast/Objectives: Sales/Expenses/ Market Share/SOV

Brand strategy

Targeting：City, hospital, physician

Field Force size and structure

Organization

Pre and Post Launch KPIs monitoring

ATU tracking

Message recall

FF/ activity effectiveness

Performance Management

44

Market Research Timeline Before Launch

+6 m.-3 m.-6 m.-9 m.

Standardized Detail Aid & promotional material Testing

Launch

Patient Flow

incl. Patient Journey

ATU Tracking – Wave 2

-12m.

ATU Tracking – Base line

Concept testing and position Validation

Physician & Patients Segmentation

Message and Story flow testing

Market Understanding

Message recall and FF effectiveness

Key trends in China’s pharmaceutical market research

More spending on the mature inline products

More consolidating of brand KPI tracking on a single platform

Increasing frequency of brand tracking

More interests in patient studies

More interests in researching the low tier/community hospitals

More studies gear to measure the results for management control (i.e. sales effectiveness monitoring)

The measurement goes to more granular and detailed

SUMMARY

China’s market landscape by its size and nature is arguably the most dynamic in the world

Fragmented markets within the big market, making market entry and access more complex

Consumers becoming more sophisticated and exposed to global influence

Major healthcare reform will likely to push for more growth in Pharma industry

More research needs seen with continued market growth and evolving market landscape